瑞舒伐他汀对轻中度高血压伴高脂血症患者炎性因子及踝臂指数的影响

Rosuvastatin on inflammatory cytokines and ankle-brachial index in mild-moderate hypertensive patients with hyperlipemia

目的观察瑞舒伐他汀对轻中度高血压伴高脂血症患者炎性因子及踝臂指数的影响。方法将100例轻中度高血压伴高脂血症患者随机分为普伐他汀组和瑞舒伐他汀组,分别口服普伐他汀10 mg,每晚1次;瑞舒伐他汀5mg,每晚1次;疗程8周,观测患者治疗前后的各项血脂指标、超敏C反应蛋白(hs-CRP)及踝臂指数(ABI)的变化。结果两组治疗前各项指标比较差异无统计学意义;与普伐他汀组比较,瑞舒伐他汀组治疗后总胆固醇(TC)、低密度脂蛋白(LDL-C)、hs-CRP降低,ABI增高(P<0.05);与治疗前比较,治疗后瑞舒伐他汀组TC、LDL-C、hs-CRP降低(P<0.05)。结论瑞舒伐他汀可明显降低轻中度高血压伴高脂血症患者各项血脂指标及hs-CRP水平,减轻血管炎性反应,并且明显改善患者的动脉弹性功能。

Objective To observe the clinical effect of rosuvastatin on inflammatory cytokines and ankle-brachial index（ABI）in mild-moderate hypertensive patients with hyperlipidemia.Methods A total of 100 mild-moderate hypertensive subjects with hyperlipidemia were randomly divided into two groups：pravastatin group（n =50,pravastatin 10 mg,qn）and rosuvastatin group（n =50,rosuvastatin 5 mg,qn）.All the subjects were observed for eight weeks.The blood lipid indexes,high sensitivity C-reactive protein（hs-CRP）and ABI were measured before and after treatment.Results Before treatment,there were no significant difference in the indexes between two groups.After treatment,ABI was significantly increased,the total cholesterol（TC）,low-density lipoprotein（LDL-C）and hsCRP were significantly decreased in pravastatin group as compared with rosuvastatin group（P〈0.05）.TC,LDL-C and hs-CRP in rosuvastatin group were significantly lower after treatment（P〈0.05）.Conclusion Rosuvastatin could significantly reduce lipid parameters and hs-CRP levels in mild-moderate hypertensive patients with hyperlipidemia,alleviate the vascular inflammation and improve arterial elasticity function obviously.